IMmune checkPoint Inhibitor Related gonAdal toxiCiTy in Premenopausal Women and Men With Melanoma

Overview

This study aims to capture information regarding the effect of immune checkpoint inhibitor (ICI) treatment for melanoma on reproductive organ function and sex hormone levels. You may be eligible for this study if you are aged 18 years or older, you have been diagnosed with melanoma (Stage II, III or IV) and you are planning to receive ICI treatment. Additional criteria will apply dependent upon your biological sex characteristics. All participants who choose to enroll in this study will be asked to complete a series of questionnaires and provide blood at 4 of their scheduled treatment visits. These visits are anticipated to add 30 minutes to the scheduled visit time. Male participants will also be asked to provide semen samples at 2 of their scheduled treatment visits. These visits are anticipated to add an additional 30 minutes to the scheduled visit time. No additional or novel treatments will be offered to participants who choose to enroll in this study, this is an observational study only. It is hoped this research will contribute important information regarding the potential toxic effects of ICI treatment on sexual and reproductive function in patients with melanoma who are receiving ICI treatment.

Detailed description

While immune checkpoint inhibitors (ICIs) are widely used in young melanoma patients and may cause immune-related side effects, their impact on human gonadal function is unknown.

Eligible patients will be identified by their oncologist and provide informed consent. Menstrual/contraceptive history, sexual function questionnaires, and blood samples for gonadal biomarkers will be collected at baseline, 3, 6, and 12 months. Semen and testicular volume (in a subset) will be assessed in men at baseline and 6 months. Patients who cease ICI before the 12 month timepoint will have also have an end of treatment assessment within 4 weeks of stopping treatment.

Patients will be asked to consent to the future use of their biological samples collected during the trial. Samples will be securely stored at Peter MacCallum Cancer Centre, coded, and linked to clinical data. Patients can request sample destruction at any time, but past analyses cannot be undone.

The Sponsor or delegate will manage trial data, while sites are responsible for data entry and resolving queries. Data will be entered into REDCap, a secure system hosted by Peter MacCallum Cancer Centre. Site staff will be trained, and only authorized personnel listed on the delegation log may complete eCRFs.

Primary outcome measures

• Change in ovarian reserve before, during and after ICI treatment [Time frame: 12 months]
• Change in testicular function before, during and after ICI treatment [Time frame: 12 months]

Secondary outcome measures (9)

• Change in ovarian function before, during and after ICI treatment [Time frame: 12 months]
• Change in menstrual pattern before, during and after ICI treatment [Time frame: 12 months]
• Change in sexual function before, during and after ICI treatment [Time frame: 12 months]
• Change in circulating cytokine levels before, during and after ICI treatment [Time frame: 12 months]
• Change in testicular function before, during and after ICI treatment [Time frame: 12 months]
• Change in semen parameters before, during and after ICI treatment [Time frame: 12 months]
• Change in sexual and erectile function before, during and after ICI treatment [Time frame: 12 months]
• Change in testicular volume before, during and after ICI treatment [Time frame: 12 months]
• Change in circulating cytokines before, during and after ICI treatment [Time frame: 12 months]

Eligibility criteria

Inclusion criteria

Patients will be eligible for inclusion in this trial if all the following criteria apply:

• Patient has provided written informed consent using the IMPACT Patient Information and Consent form (PICF)
• Diagnosis of melanoma (Stage II, III or IV) in the de novo or recurrent setting
• Has a life expectancy of greater than or equal to 1 year
• Planned to receive ICI treatment, either in the neoadjuvant, adjuvant or metastatic setting, including as:

• Monotherapy
• Combination therapy

For cohort 1: premenopausal women with melanoma

• Age greater than or equal to 18 and less than or equal to 45 years at the time of signing consent
• Patient is premenopausal (defined as baseline FSH within the premenopausal range per local laboratory at registration). Women on hormonal contraception who have an abnormal FSH level, will be included if their AMH level is greater than or equal to 1.0 pmol/L at registration
• AMH level greater than or equal to 1.0 pmol/L at registration

For Cohort 2: men with melanoma

• Age greater than or equal to 18 and less than or equal to 60 years at the time of signing consent
• Fasting morning total testosterone, LH and FSH within the normal range (per local laboratory) at the time registration

Exclusion criteria

Patients will not be eligible for inclusion in this trial if any of the following criteria apply:

• Previous removal of both ovaries (females) or previous removal of both testes or previous vasectomy (males)
• Planned for or previously had pelvic radiotherapy
• Any medications within the prior 6 months known to disrupt the hypothalamic pituitary gonadal axis, e.g., GnRH agonists or antagonists, selective estrogen receptor modulators (SERMs), aromatase inhibitors, testosterone, anabolic steroids, etc.
• Previous or concurrent alkylating or platinum-based chemotherapy within the last 2 years
• Previous use of ICI
• History of hypogonadism
• Presence of any psychological, social, geographical, or other condition for which, in the opinion of the site Investigator, participation would not be in the best interest of the patient (e.g., compromise the well-being) or that could prevent, limit, or confound the protocol-specified assessments

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Observational model

Cohort

Study locations

Australia · 6 centers

• Melanoma Institute Australia — Sydney
• Princess Alexandra Hospital — Brisbane
• Cairns Base Hospital — Cairns
• Peter MacCallum Cancer Centre — Melbourne
• The Alfred Hospital — Melbourne
• Austin Hospital — Melbourne

Identifiers

NCT: NCT07138222 · HREC/117978/PMCC · ACTRN12625000395437p

Primary sources (government registries)

• ClinicalTrials.gov (US NIH)

View this study on ClinicalTrials.gov ↗